Clinical Trial

A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Malignant Solid Tumors

Enrolling by Invitation Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated November 26, 2025 (before its estimated May 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a Phase 1 open-label study to evaluate the safety, tolerability, and pharmacokinetics of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) at dose of 5×10∧9VP、5×10∧10VP、5×10∧11VP in Patients With Malignant Solid Tumors. Subjects will be treated with a single dose of BioTTT001 Injection after the screening period.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-01-18; most recent amendment 2025-11-25.
Status change: Not Yet Recruiting → Enrolling by Invitation 2025-01-02
Trial Details
NCT Number NCT06215846
Lead Sponsor Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Conditions Solid Tumor
Enrollment 12 participants
Start Date 2024-05-07
Primary Completion 2026-05-30 (estimated)
Study Completion 2026-06-28 (estimated)
Updated on ClinicalTrials.gov 2025-11-26